{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:56:28Z","timestamp":1792443388999,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["21267"],"award-info":[{"award-number":["21267"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["21267"],"award-info":[{"award-number":["21267"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["NET-2018-12365935"],"award-info":[{"award-number":["NET-2018-12365935"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-022-00713-6","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T02:03:36Z","timestamp":1660269816000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0816-5462","authenticated-orcid":false,"given":"Giacomo","family":"Coltro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4810-6501","authenticated-orcid":false,"given":"Francesco","family":"Mannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6241-1206","authenticated-orcid":false,"given":"Giuseppe Gaetano","family":"Loscocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Mannarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Rotunno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Maccari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Pancani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Atanasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-0730","authenticated-orcid":false,"given":"Alessandro Maria","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"713_CR1","first-page":"2895","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, J Am Soc Hematol. 2009;113:2895\u2013901.","journal-title":"Blood, J Am Soc Hematol"},{"key":"713_CR2","first-page":"1703","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood, J Am Soc Hematol. 2010;115:1703\u20138.","journal-title":"Blood, J Am Soc Hematol"},{"key":"713_CR3","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2010","unstructured":"Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2010;29:392\u20137.","journal-title":"J Clin Oncol"},{"key":"713_CR4","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","volume":"36","author":"P Guglielmelli","year":"2017","unstructured":"Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2017;36:310\u20138.","journal-title":"J Clin Oncol"},{"key":"713_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1600-0609.2009.01373.x","volume":"84","author":"MM Patnaik","year":"2010","unstructured":"Patnaik MM, Caramazza D, Gangat N, Hanson CA, Pardanani A, Tefferi A. Age and platelet count are IPSS\u2010independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. Eur J Haematol. 2010;84:105\u20138.","journal-title":"Eur J Haematol"},{"key":"713_CR6","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.1200\/JCO.2009.22.8833","volume":"27","author":"CS Tam","year":"2009","unstructured":"Tam CS, Kantarjian H, Cortes J, Lynn A, Pierce S, Zhou L, et al. Dynamic model for predicting death within 12 months in patients with primary or post\u2013polycythemia vera\/essential thrombocythemia myelofibrosis. J Clin Oncol. 2009;27:5587.","journal-title":"J Clin Oncol"},{"key":"713_CR7","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/leu.2011.374","volume":"26","author":"A Tefferi","year":"2012","unstructured":"Tefferi A, Pardanani A, Gangat N, Begna K, Hanson C, Van Dyke D, et al. Leukemia risk models in primary myelofibrosis: an International Working Group study. Leukemia 2012;26:1439\u201341.","journal-title":"Leukemia"},{"key":"713_CR8","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","volume":"88","author":"B Dupriez","year":"1996","unstructured":"Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88:1013\u20138.","journal-title":"Blood"},{"key":"713_CR9","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/cncr.21644","volume":"106","author":"D Dingli","year":"2006","unstructured":"Dingli D, Schwager SM, Mesa RA, Li CY, Tefferi A. Prognosis in transplant\u2010eligible patients with agnogenic myeloid metaplasia: a simple CBC\u2010based scoring system. Cancer: Interdiscip Int J Am Cancer Soc. 2006;106:623\u201330.","journal-title":"Cancer: Interdiscip Int J Am Cancer Soc"},{"key":"713_CR10","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.leukres.2006.12.025","volume":"31","author":"M Elliott","year":"2007","unstructured":"Elliott M, Verstovsek S, Dingli D, Schwager S, Mesa R, Li C, et al. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res. 2007;31:1503\u20139.","journal-title":"Leuk Res"},{"key":"713_CR11","doi-asserted-by":"crossref","unstructured":"Vainchenker W, Constantinescu SN, Plo I. Recent advances in understanding myelofibrosis and essential thrombocythemia. F1000Res. 2016;5:F1000 Faculty Rev-700.","DOI":"10.12688\/f1000research.8081.1"},{"key":"713_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.clml.2020.01.008","volume":"20","author":"BK Marcellino","year":"2020","unstructured":"Marcellino BK, Verstovsek S, Mascarenhas J. The myelodepletive phenotype in myelofibrosis: clinical relevance and therapeutic implication. Clin Lymphoma Myeloma Leuk. 2020;20:415\u201321.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"713_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-021-03573-3","volume":"12","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Song D, Guo J, Jin J, Tao Y, Zhang Z, et al. U2AF1 mutation promotes tumorigenicity through facilitating autophagy flux mediated by FOXO3a activation in myelodysplastic syndromes. Cell Death Dis. 2021;12:1\u201312.","journal-title":"Cell Death Dis"},{"key":"713_CR14","doi-asserted-by":"crossref","unstructured":"Biancon G, Joshi P, Zimmer JT, Hunck T, Gao Y, Lessard MD, et al. Multi-omics profiling of U2AF1 mutants dissects pathogenic mechanisms affecting RNA granules in myeloid malignancies. bioRxiv. 2021.","DOI":"10.1101\/2021.04.22.441020"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00713-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00713-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00713-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T15:10:29Z","timestamp":1669216229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00713-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":14,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["713"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00713-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]},"assertion":[{"value":"30 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AMV has received speaker fees from Novartis, AOP Health, Incyte, AbbVie, GlaxoSmithKline (GSK), and Bristol Myers Squibb (BMS); and has participated to the advisory boards of Novartis, Incyte, AOP Orphan Pharmaceuticals, AbbVie, GSK, BMS, and Roche. PG has received speaker fees from AbbVie and Novartis, and support for attending meetings from Sanofi. The other authors have nothing to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}